Perrigo Company plc Finite-Lived Intangible Asset, Expected Amortization, Year One
Perrigo Company plc (PRGO) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $219.70 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $219.70M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $212.20M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $239.80M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $275.80M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $219.70M 10-K · filed 2026-02-26 |
| 2024-12-31 | $212.20M 10-K · filed 2025-02-28 |
| 2023-12-31 | $239.80M 10-K · filed 2024-02-27 |
| 2022-12-31 | $275.80M 10-K · filed 2023-02-28 |
| 2021-12-31 | $194.90M 10-K · filed 2022-03-01 |
| 2020-12-31 | $282.20M 10-K · filed 2021-03-01 |
| 2019-12-31 | $284.40M 10-K · filed 2020-02-27 |
| 2018-12-31 | $300.00M 10-K · filed 2019-02-27 |
| 2017-12-31 | $341.00M 10-K · filed 2018-03-01 |
| 2016-12-31 | $339.50M 10-K · filed 2017-05-22 |
| 2015-12-31 | $603.10M 10-KT · filed 2016-02-25 |
| 2015-06-27 | $589.10M 10-K · filed 2015-08-13 |
| 2014-06-28 | $427.00M 10-K · filed 2014-08-14 |
| 2014-03-29 | $109.00M 10-Q · filed 2014-05-07 |
| 2013-12-28 | $214.60M 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |